Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates.
The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June 30, 2026. Profits were less than half what they were a year ago, while revenue was down 8.1% compared with Q3 2025.
Adjusted to exclude one-time items, earnings per share were 56¢, more than double the analyst consensus of 27¢ on revenue of $254.5 million.
“Our third quarter results improved significantly on a sequential basis… due to a combination of factors, including improved performance within the United States and International, as well as contribution from the [$199.4 million] acquisition of [auto-injector maker] Owen Mumford which closed midway through our third quarter,” said Devdatt Kurdikar, chair, president and CEO of Embecta. “We repaid approximately $53 million of debt during the quarter and also repurchased approximately $9 million of shares under our three-year, up to $100 million share repurchase program. While our GLP-1 B2B partners launched generic GLP-1 therapies co-packaged with our pen needles in Canada and Brazil.”
The company said it expects to log adjusted EPS of $1.80 to $1.90 this year, up from prior guidance of $1.55 to $1.75, and maintained its top-line outlook of $1.015 billion to $1.035 billion.
Embecta stock was up 30.73% over the past week.
